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Abstract
Background: Inducible costimulator (ICOS), a costimulatory molecular of the CD28 family, provides positive signal to
enhance T cell proliferation. Its abnormal expression can disturb the immune response and entail an increased risk
of cancer. To investigate whether single nucleotide polymorphisms (SNPs) in the ICOS gene are associated with
sporadic breast cancer susceptibility and progression in Chinese women, a case-control study was conducted.
Methods: In the study cohort, we genotyped five SNPs (rs11889031, rs10932029, rs4675374, rs10183087 and
rs10932037) in ICOS gene among 609 breast cancer patients and 665 age-matched healthy controls. Furthermore,
the positive results were replicated in an independent validation cohort of 619 patients and 682 age-matched
healthy controls. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to
determine the genotypes.
Results: In rs10932029, compared with TT genotype and T allele, the CT genotype and C allele showed a
significantly increased risk of breast cancer (P = 0.030, OR = 1.467, 95% CI 1.037-2.077; P = 0.017, OR = 1.481, 95%
CI 1.070-2.049, respectively), and the associations were also significant in the validation cohort (P = 0.002, OR =
1.693, 95% CI 1.211-2.357; P = 0.003, OR = 1.607, 95% CI 1.171-2.204, respectively). Haplotype analysis showed that
CTCAC haplotype containing rs10932029 T allele had a lower frequency in cases than in controls (P = 0.015),
whereas haplotype CCCAC containing rs10932029 C allele was more common in cases than in controls (P = 0.013).
In the analysis of clinicopathologic features, rs11889031 CT genotype and T allele were associated with
progesterone receptor (PR) status and lymph node metastasis, which were further supported by our validation
cohort. Moreover, some haplotypes were associated with estrogen receptor (ER) and PR statuses.
Conclusions: These results indicate that ICOS gene polymorphisms may affect the risk of breast cancer and show
that some SNPs are associated with breast cancer characteristics in a northern Chinese population.
Background
Breast cancer is one of the most common malignant
tumors contributing to the high mortality of females
worldwide. The etiology of breast cancer is a complex
combination of both environmental and genetic factors,
so the determination of genetic polymorphism provided
a new way to investigate the etiology of such complex
genetic disease. Accordingly, significant associations
have been demonstrated on some gene polymorphisms
with breast cancer risk [1]. So far, accumulating evi-
dence convincingly emphasizes that the host immune
system is involved in the regulation of cancer develop-
ment and progression. T lymphocyte, whose function is
central to the adaptive immune response, plays a critical
role in immune surveillance of cancer cells [2,3]. There-
fore, the molecules, in particular the costimulatory ones,
mediating regulation of T-cell activity may influence
cancer susceptibility [4]. Inducible costimulator (ICOS)
molecule is a member of the CD28 family that generates
indispensable secondary signals to determine the activa-
tion and development of the immune response.
T h eg e n ee n c o d i n gICOS is located on chromosome
2q33, which contains CD28 and CTLA-4,a n o t h e rt w o
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cells, ICOS is induced following T cell activation [5].
Interaction between ICOS and its ligand (ICOS-L;
CD275), a molecule highly expressed on B cells and
dendritic cells, provides costimulatory signal to induce
T cell proliferation, secretion of various cytokines and
up-regulation of cell surface molecules [6]. Blocking of
ICOS with Abs or an ICOS-Ig fusion protein results in
the inhibition of immune responses mediated by Th1
and Th2 [7,8]. Furthermore, a recent research revealed
that impaired function of CD4
+ and CD8
+ T cells were
observed in ICOS-deficient patients [9].
Although the polymorphisms in ICOS gene have been
extensively studied in various diseases, including cancers
[10,11], the association between ICOS gene polymorph-
isms and the risk of breast cancer remains unclear. To
determine the key roles of ICOS in tumor immunity, we
genotyped five potentially functional SNPs, including
rs11889031, rs10932029 (IVS1+173), rs4675374,
rs10183087 (c.602) and 10932037 (c.1624), and investi-
gate their associations with both the risk and clinico-
pathologic features of breast cancer in Chinese women
from Heilongjiang Province, northeast of China.
Methods
Study population
This study cohort contained 609 sporadic breast cancer
cases and 665 healthy controls. All cases (mean age at
49.5 ± 10.1 years) with histopathologically confirmed
breast cancer were recruited from the Department of
Breast Surgery in the Third Affiliated Hospital of Harbin
Medical University, and their pathological and clinical
information were obtained from medical files (Table 1),
the controls were frequency-matched to cases by age
(mean age at 48.0 ± 9.9 years) and were volunteers with-
out any history of cancer. Both breast cancer cases and
healthy controls were hereditarily unrelated and were
recruited from Heilongjiang Province, northeast of
China. The validation cohort consisted 619 breast can-
cer cases (mean age at 49.9 ± 10.2 years) and 682 age-
matched healthy controls (mean age at 48.9 ± 10.0
years), and the selection criteria for cases and controls
was as described above. At recruitment, each subject
h a ds i g n e dt h ew r i t t e ni n f o r m e dc o n s e n t ,a n dp r o v i d e d
5 ml venous blood from 2006 to 2010. The study was
approved by the institutional ethical review board.
DNA extraction and genotyping
Genomic DNA was extracted from frozen whole blood
using the universal genomic DNA Extraction Kit
VER.3.0 (TaKaRa, Japan). Genotyping was performed by
polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) method. The polymorphic
region was amplified by PCR using a T-Gradient
Thermoblock PCR System (Biometra, Germany) in a 25
ul reaction solution containing 0.3 ug genomic DNA, 2.5
ul 10× PCR buffer (Mg2+ plus), 0.2 ul dNTPs mixture,
2.5 U TaqDNA polymerase (TaKaRa, Japan) and 0.1 ul of
each primer (Invitrogen, China). Primers sequences of
each SNP were rs11889031 (F:5’-CA AACTGAGAAGC-
GAGAG-3’,R : 5 ’-ATAAGTTCTAGAGCTCAGGG-3’),
rs10932029 (F:5’-CCTCTGGTA TTTCTTTCTCTTC-3’,
R:5’-ACAGGTAACTCCAAGCAGG-3’), rs4675374 (F:5’-
TGTTTCATCTTGTG CTGG-3’,R :5 ’-ACCATGCAGT-
TACCTTCC-3’), rs10183087 (F:5’-TATGAAAGG-
CAATGGAGAGG-3’,R : 5 ’-ATGATAGTGAAATGCGG
ACAG-3’), rs10932037 (F:5’-CATTATCTATGTTTT-
CATGGTATT-3’,R : 5 ’-AGGCTATCTTGAAGGGC-
CAG-3’). Annealing temperature were rs11889031 (58°
Table 1 Clinicalpathologic features of breast cancer
patients
Feature Study cohort Validation cohort
Case no (%) Case no (%)
Tumor type
IDC 523(85.88) 528(85.30)
MC 7(1.15) 6(0.97)
Intraductal carcinoma 40(6.57) 45(7.27)
Mucinous adenocarcinoma 14(2.30) 13(2.10)
Others 25(4.11) 27(4.36)
Tumor size(cm)
TZ ≤ 2 210(34.48) 200(32.31)
2<T Z≤ 5 277(45.48) 289(46.69)
TZ > 5 29(4.76) 37(5.98)
Unknown 93(15.27) 93(15.02)
LN involvement
Positive 263(43.19) 278(44.91)
Negative 334(54.84) 333(53.80)
Unknown 12(1.97) 8(1.29)
ER
Positive 313(51.40) 361(58.32)
Negative 208(34.15) 207(33.44)
Unknown 88(14.45) 51(8.24)
PR
Positive 382(62.73) 345(55.74)
Negative 134(22.00) 223(36.03)
Unknown 93(15.27) 51(8.24)
P53
Positive 153(25.12) 144(23.26)
Negative 353(57.96) 420(67.85)
Unknown 103(16.91) 55(8.89)
C-erbB-2
Positive 198(32.51) 187(30.21)
Negative 317(52.05) 379(61.23)
Unknown 94(15.44) 53(8.56)
Abbreviations: IDC = infiltrative ductal carcinoma; MC = medullary carcinoma;
LN = lymph node; TZ = tumor size; ER = estrogen receptor; PR =
progesterone receptor
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Page 2 of 7C), rs10932029 (55.8°C), rs4675374 (56°C), rs10183087
(58°C) and rs10932037 (61°C). The lengths of PCR pro-
ducts were 586 bp (rs11889031), 317 bp (rs10932029),
301 bp (rs4675374), 520 bp (rs10183087) and 445 bp
(rs10932037). The PCR products were digested with
restriction enzymes (NEB, UK) according to the manu-
facturer’s instruction and analyzed by 2% (rs11889031,
rs10932029, rs4675374, rs10183087) and 4%
(rs10932037) agarose gel electrophoresis (Additional file
1, Figure S1). Restriction enzymes of each SNP were
XmnI (rs11889031), Ddel (rs10932029), Ddel
(rs4675374), Hpy188III (rs10183087) and NlaIII
(rs10932037). The digested fragments length of each SNP
were rs11889031 (T: 401+185 bp, C: 586 bp), rs10932029
(C: 220+97 bp, T: 317 bp), rs4675374 (C:252+49 bp,
T:301 bp), rs10183087 (C:283+133+104 bp, A:283+237
bp) and rs10932037 (C: 270+86+70+19 bp, T: 270+156
+19 bp). In order to confirm the accuracy of genotyping
results, 10% of the samples of each SNP were randomly
selected to be tested twice by different persons. Further-
more, 3% random samples of each SNP were confirmed
by direct sequencing, and the reproducibility of both was
100%. SNPs with suggestive statistical significance in the
study cohort were replicated in an independent validation
cohort to validate the results.
Statistical analysis
Genotype frequencies of five SNPs were tested for
Hardy-Weinberg equilibrium (HWE). We used Haplo-
view 4.1 to tag all common haplotypes and their fre-
quencies in cases and controls. Associations between
SNPs and breast cancer risk were estimated by odds
ratio (OR) and 95% confidence interval (CI) using
unconditional logistic regression with adjustment for
age. Disease characteristics were compared in patient
using the chi-square test and Fisher’se x a c tt e s t .H o m o -
zygotes for the major allele were the reference group,
and then heterozygotes and minor allele homozygotes
were compared with the reference group, respectively.
All statistical tests were two-sided, and statistical signifi-
cance was set at P < 0.05. Statistical analyses were per-
formed using SPSS 16.0 software.
Results
ICOS gene polymorphisms and the risk of breast cancer
The genotype and allele frequencies of five SNPs in the
study cohort are shown in Table 2. No deviation from
HWE was found in the genotype distribution of the five
SNPs in controls (P > 0.05). In rs10932029, compared
with TT genotype and T allele, the frequencies of CT
genotype and C allele were higher in cases than those in
controls (P = 0.030, OR = 1.467, 95% CI 1.037-2.077; P
= 0.017, OR = 1.481, 95% CI 1.070-2.049, respectively).
However, no significant differences were found between
the alleles and genotypes of the other SNPs and the risk
of breast cancer. To confirm this genetic association, we
replicated rs10932029 in an independent validation
cohort, and the associations remained suggestive in the
validation cohort (P = 0.002, OR = 1.693, 95% CI 1.211-
2.357; P = 0.003, OR = 1.607, 95% CI 1.171-2.204,
respectively). We further analyzed the association
between haplotypes and the risk of breast cancer. The
haplotypes with frequency > 1% are shown in Table 3.
CTCAC (11889031 C, rs10932029 T, 4675374 C,
10183087 A, 10932037 C) was the most frequent haplo-
type appeared in cases and controls (35.7%), and the fre-
quency of this haplotype was lower in patients than in
healthy controls (P = 0.015). Moreover, CCCAC haplo-
type had a higher frequency in cases (P = 0.013).
ICOS gene polymorphisms and clinicopathologic features
ICOS gene polymorphisms were also analyzed to estab-
lish their associations with clinicopathologic features,
including lymph node metastasis, tumor size and the
statuses of estrogen receptor (ER), progesterone receptor
( P R ) ,C - e r b B - 2a n dP 5 3 .T h ep o s i t i v er e s u l t si no u r
study cohort are shown in Table S1. In rs10932029,
compared with TT genotype, the frequency of CT geno-
type was lower in C-erbB-2 positive cases than negative
ones (P = 0.046), but this result failed to be confirmed
in the validation cohort (Additional file 2, Table S1). In
rs11889031, compared with CC genotype and C allele,
CT genotype and T allele had lower frequencies in PR
positive cases (P = 0.002; P = 0.017, respectively),
furthermore, CT genotype and T allele had lower fre-
quencies in lymph node involvement (P = 0.011; P =
0.038, respectively). And these positive results were also
confirmed in our validation cohort (Additional file 2,
Table S1). However, no statistical association was
obtained between five SNPs and the tumor size, ER or
P53 statuses.
We also analyzed the association between haplotypes
and clinical features of cases. The frequency of CTCCC
haplotype was higher in ER positive cases (P = 0.008)
and the CTTAC haplotype had a lower frequency in
both ER positive and PR positive cases (P = 0.034; P =
0.005, respectively). However, no significant association
was observed between haplotypes and lymph node
involvement, tumor size, C-erbB-2 or P53 statuses.
Discussion
The etiology of breast cancer is complicated, in which
the genetic factor plays an important role. Although
high-penetrant susceptibility genes such as BRCA1 and
BRCA2 demonstrate potent associations with the famil-
iar breast cancer, many low-penetrant susceptibility
genes predisposing to breast cancer remain to be eluci-
dated. Previous studies showed that SNPs of Cytotoxic T
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Page 3 of 7Table 2 Genotype and allele frequencies of ICOS polymorphisms and their associations with breast cancer risk
SNP Study cohort Validation cohort
Genotype
and allele
Cases
n = 609(%)
Controls
n = 665(%)
OR (95% CI)
5 P value Cases
n = 619(%)
Controls
n = 682(%)
OR (95% CI)
5 P value
rs11889031
1 CC 248(40.92) 281(43.03) reference
CT 286(47.19) 293(44.87) 1.104(0.872,1.398) 0.411
TT 72(11.88) 79(12.10) 1.025(0.713,1.472) 0.896
C 782(64.52) 855(65.47) reference
T 430(35.48) 451(34.53) 1.039(0.882,1.224) 0.647
rs10932029 TT 523(85.88) 599(90.08) reference 522(84.33) 614(90.03) reference
CT 82(13.46) 64(9.62) 1.475(1.042,2.088) 0.029 95(15.35) 66(9.68) 1.693(1.201,2.350) 0.002
CC 4(0.66) 2(0.30) 2.348(0.427,12.904) 0.326 2(0.32) 2(0.29) 1.171(0.164,8.353) 0.875
T 1128(92.61) 1262(94.89) reference 1139(92.00) 1294(94.87) reference
C 90(7.39) 68(5.11) 1.490(1.076,2.063) 0.016 99(8.00) 66(5.13) 1.595(1.162,2.189) 0.004
rs4675374
2 CC 136(22.48) 165(25.82) reference
CT 320(52.89) 325(50.86) 1.193(0.907,1.571) 0.207
TT 149(24.63) 149(23.32) 1.216(0.882,1.677) 0.233
C 592(48.93) 655(51.25) reference
T 618(51.07) 623(48.75) 1.099(0.939,1.286) 0.241
rs10183087
3 AA 438 (72.16) 487(74.01) reference
AC 154(25.37) 155(23.57) 0.909(0.702,1.177) 0.469
CC 15(2.47) 16(2.43) 0.951(0.454,1.993) 0.894
A 1030(84.84) 1129(85.79) reference
C 184(15.16) 187(14.21) 0.998(0.826,1.158) 0.795
rs10932037
4 CC 568(93.42) 618(94.93) reference
CT 40(6.58) 33(5.07) 1.326(0.824,2.133) 0.245
TT 0 0 ––
C 1176(96.71) 1269(97.47) reference
T 40(3.29) 33(2.53) 1.315(0.823,2.100) 0.252
1 cases n = 606, missing n = 3; controls n = 653, missing n = 12.
2 cases n = 605, missing n = 4; controls n = 639, missing n = 26.
3 cases n = 607, missing n = 2; controls n = 658, missing n = 7.
4cases n = 608, missing n = 1; controls n = 651, missing n = 14.
5ORs were adjusted for age
Abbreviations: OR = odds ratio; CI = confidence interval
Table 3 ICOS haplotype (rs11889031, rs10932029, rs4675374, rs10183087, rs10932037) frequencies in cases and
controls
ICOS haplotype Frequency Cases
(n = 609)
controls
(n = 665)
P value
rs11889031 rs10932029 rs4675374 rs10183087 rs10932037
C T C A C 0.357 0.333 0.379 0.015
T T T A C 0.289 0.294 0.285 0.651
C T T A C 0.145 0.152 0.139 0.385
C T C C C 0.051 0.047 0.055 0.382
C C C A C 0.037 0.047 0.028 0.013
T T T C C 0.028 0.031 0.026 0.501
C T T C C 0.020 0.020 0.020 0.974
C C C C C 0.017 0.018 0.016 0.674
T T C A C 0.016 0.016 0.016 0.966
C T C C T 0.010 0.013 0.007 0.150
Abbreviations: OR = odds ratio; CI = confidence interval
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cyte attenuator (BTLA) might confer susceptibility to
breast cancer, which suggests the critical role of costi-
mulatory molecules in the development of breast cancer
[12,13]. In addition, CTLA-4 and ICOS are located
within a stretch of 100 kb on chromosome 2q33. Trea-
ted with CTLA-4 blockade, ICOS expressed higher on
CD4
+ T cells from peripheral blood and tumor tissues
of bladder cancer patients and this CD4
+ICOS
hi Tc e l l
population produced higher IFN-g, indicating that ICOS
interacts with CTLA-4 and plays an important role in
tumor immunity [14,15]. Thus, we predicted that ICOS
gene polymorphisms might also be related to the risk of
breast cancer. In this study, we analyzed five potentially
functional SNPs in ICOS gene, including rs11889031C/T
in promotor, rs10932029 C/T and rs4675374C/T in the
intron1, rs10183087A/C and rs10932037 C/T in the 3’-
untranslating region (UTR), and determine their associa-
tions with breast cancer. Here, we first report that some
of the alleles, genotypes and haplotypes of the above
SNPs are associated with the risk and clinicopathological
features of breast cancer.
This case-control study on the variants in the ICOS
gene revealed that only rs10932029 may confer suscept-
ibility to breast cancer. The association between
rs10932029 C/T and breast cancer risk found in the
study cohort was also observed in the validation cohort.
Patients carrying rs10932029 CT genotype and C allele
had an increased risk of breast cancer, which indicates
that CT genotype and C allele may play risk roles in
breast cancer. Rs10932029 C/T and rs4675374 C/T are
both located in intron1 of ICOS. Introns are important
for mRNA processing and transporting. Many studies
have demonstrated the presence of regulatory elements
and splicing control elements in mammalian introns,
particularly in the first intron. Moreover, mutations
occurring in introns can induce the aberrant splicing
due to the disruption of splicing enhancers and altera-
tion of the pre-mRNA, as a result, impair the transla-
tion efficiency [16-18]. Rs10932029 is a well studied
variant in some diseases. Interestingly, one study
demonstrated that this SNP could influence the expres-
sion of CTLA4 isoforms [19], but later study could not
confirm this conclusion [20]. Although a correlation
between rs10932029 and breast cancer risk was ascer-
tained in our study, the mechanism underlying this
result is not immediately evident. The potential explana-
tion might be concluded as follows. Firstly, this poly-
morphism might regulate ICOS mRNA processing and
translation. Secondly, CT genotype and C allele might
down-regulate the ICOS expression and then increase
the breast cancer risk. However, rs4675374 located in
the same intron did not show any association with the
risk of breast cancer.
Allelic variants located in the promoter region may
change the motif of functional DNA binding sites and
thereby affect their affinities for the relevant transcrip-
tion factors. Notably, with a location in the promoter
region, rs11889031 is situated in the NF-B binding site
[21]. However, although this potentially functional var-
iant may affect the function of the gene, our data did
not show any association between this SNP and the risk
of breast cancer.
Rs10183087 A/C and rs10932037 C/T are both
located in the 3’-UTR of the ICOS. Multiple regulatory
elements in 3’-UTR can affect mRNA stability and
degradation as well as nuclear export [22]. Using the
PupaSuite software [23], rs10183087 is speculated to be
located in the exonic splicing enhancers(ESE), so it may
influence mRNA splicing, eventually, affect protein func-
tion. One previous study showed that rs10183087 was
associated with delayed graft function [24], but no rela-
tion was found in malignant melanoma susceptibility
[11]. Our study also did not show any statistical signifi-
cant association between this SNP and the risk of breast
cancer. Therefore, whether this SNP affect ICOS func-
tion needs to be further studied. Additionally,
rs10932037A/C was located in a MicroRNA-binding
site. Altering the strength of miRNA binding, SNPs in
3’UTR targeted by miRNAs were associated with the
risk of breast cancer [25,26]. In line with this hypothesis,
one study had verified that rs10932037 can regulate the
expression of ICOS mRNA [19]. However, we failed to
find the association between rs10932037 and the sus-
ceptibility to breast cancer. The correlation between
rs10932037 and genetic susceptibility to a variety of dis-
eases has been widely studied, but the results were
inconsistent. Rs10932037 was proposed to be associated
with kidney graft survival and the outcome of hemato-
poietic stem cell transplantation (HSCT) [24,27], but
another study about gastric mucosa-associated lymphoid
tissue lymphoma did not show any significant associa-
tion [10]. Considering the minor allele frequency of
rs10932037 was 2.53% in controls, further study using a
large sample size is needed to confirm this association.
We further analyzed the association between haplo-
types and the risk of breast cancer. We found that
CTCAC haplotype containing rs10932029 T allele
appeared to be protective against breast cancer, whereas
CCCAC haplotype containing rs10932029 C allele may
be a risk factor in breast cancer. This result also high-
lighted the important role for rs10932029.
In addition, we found that ICOS gene polymorph-
isms were associated with clinicopathologic features of
breast cancer patients. For rs10932029, a correlation
was found between it and C-erbB-2 status in the study
cohort, but no relation was found in the validation
cohort. As it is known, the over-expression of C-erbB-
Xu et al. BMC Cancer 2011, 11:392
http://www.biomedcentral.com/1471-2407/11/392
Page 5 of 72 can lead to insensitive endocrine treatment, the
recurrence and metastasis of tumor, resulting in poor
prognosis and overall survival [28,29]. Nevertheless, in
consideration of the converse results in two indepen-
dent cohorts, whether rs10932029 was associated with
C-erbB-2 status needs to be further investigated. We
also found that rs11889031 was associated with PR sta-
tus and lymph node metastasis in both study and vali-
dation cohorts. The expression of ER or PR has long
been regarded as predictive markers of breast cancer
endocrine therapy [30,31]. Moreover, cases of positive
lymph node metastasis have higher mortality [32]. So
our data indicate that genotypes and alleles in
rs11889031 may be important in forecasting the prog-
nosis of breast cancer.
In the analysis of the association between haplotypes
and clinicopathlogical features, we observed that
CTTAC and CTCCC haplotypes were associated with
ER expression, and CTTAC haplotype showed a correla-
tion with the status of PR. Therefore, these two haplo-
types may provide valuable prognostic information for
the survival of breast cancer patients.
Conclusions
This study first established that SNPs in the ICOS gene
may affect breast cancer risk and some SNPs were also
associated with clinical characteristics of breast cancer
in Chinese women from northeast of China. However,
studies focusing on other critical polymorphisms in dif-
ferent populations and investigations of biological func-
tions of ICOS gene polymorphisms remain to be further
conducted.
Additional material
Additional file 1: Figure S1. Polymerase chain reaction-restriction
fragment length polymorphism analysis of ICOS polymorphisms. This
figure showed the restriction fragment length of each SNP (A for
rs11889031, B for rs10932029, C for rs4675374, D for rs10183087 and E
for rs10932037).
Additional file 2: Table S1. ICOS polymorphisms and clinical features in
cases in the study cohort and validation cohort. This table showed the
positive results about the association between two SNPs (rs10932029 and
rs11889031) and clinicopathologic features, including lymph node
metastasis and the statuses of progesterone receptor (PR) and C-erbB-2.
Abbreviations
CI: Confidence interval; ER: Estrogen receptor; HWE: Hardy-Weinberg
equilibrium; ICOS: Inducible costimulator; CTLA-4: Cytotoxic T lymphocyte
antigen -4; LN: Lymph node; OR: Odds ratio; PCR-RFLP: Polymerase chain
reaction-restriction fragment length polymorphism; PR: Progesterone
receptor; SNP: Single nucleotide polymorphisms; TZ: Tumor size.
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